US4582824A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for inhibiting activities of platelet activating factor
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1983-08-31
•
Granted: 1986-04-15
•
Expires: 2003-08-31
Abstract
Abstract Compounds of the formula ##STR1## wherein R 1 is a C 10-24 alkyl group, R 2 is a C 1-4 alkyl group or a phenyl-C 1-3 alkyl group and A + is a heterocyclic group containing a quaternized nitrogen, and physiologically acceptable salts thereof have platelet activating factor inhibiting activity and are useful in the prevention and treatment of various circulatory diseases or allergic diseases.
Inventors
- 👤 Kohei Nishikawa
- 👤 Susumu Tsushima
- 👤 Hiroaki Nomura
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 04:31
CPC Classifications
C; C07; C07F; C07F9/00; C07F9/02; C07F9/06; C07F9/08; C07F9/09; C07F9/10; A; A61; A61P; A61P9/00; C07F9/547; C07F9/553; C07F9/576; C07F9/58; C07F9/62; C07F9/6536; C07F9/6539
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
68 words
A method for inhibiting activities of platelet activating factor in mammals which comprises administering to a mammal a therapeutically effective amount of a compound of the formula ##STR10## wherein R 1 is a C 10-24 alkyl group, R 2 is a C 1-4 alkyl group or a phenyl-C 1-3 alkyl group and A + is a heterocyclic group containing a quaternized nitrogen, or a physiologically acceptable salt thereof.
Claim 2
Independent Claim
68 words
A method for inhibiting activities of platelet activating factor in mammals which comprises administering to a mammal a therapeutically effective amount of a compound of the formula ##STR10## wherein R 1 is a C 10-24 alkyl group, R 2 is a C 1-4 alkyl group or a phenyl-C 1-3 alkyl group and A + is a heterocyclic group containing a quaternized nitrogen, or a physiologically acceptable salt thereof.
Claim 3
Dependent Claim
15 words
The method according to claim 1, wherein R 1 is a C 14-20 alkyl group.
Claim 4
Dependent Claim
15 words
The method according to claim 1, wherein R 1 is a C 15-18 alkyl group.
Claim 5
Dependent Claim
11 words
The method according to claim 1, wherein R 1 is n-octadecyl.
Claim 6
Dependent Claim
15 words
The method according to claim 1, wherein R 2 is a C 1-4 alkyl group.
Claim 7
Dependent Claim
11 words
The method according to claim 1, wherein R 2 is methyl.
Claim 8
Dependent Claim
37 words
The method according to claim 1, wherein A + is pyridinio, oxazolio, isoxazolio, thiazolio, isothiazolio, pyridazinio, quinolinio or isoquinolinio, said group being substituted or unsubstituted by C 1-4 alkyl, hydroxy, hydroxyethyl, aminoethyl, amino, imino, carbamoyl or ureido.
Claim 9
Dependent Claim
15 words
The method according to claim 1, wherein A + is pyridinio, thiazolio, (4-methyl-5-hydroxyethyl)thiazolio or isoquionolinio.
Claim 10
Dependent Claim
11 words
The method according to claim 1, wherein A + is thiazolio.
Claim 11
Dependent Claim
28 words
The method according to claim 1, wherein R 1 is a C 15-18 alkyl group, R 2 is a C 1-4 alkyl group and A + is thiazolio.
Claim 12
Dependent Claim
30 words
The method according to claim 1, wherein the compound (I) or a physiologically acceptable salt thereof is administered for the prevention or treatment of a platelet activating factor-induced circulatory disease.
Claim 13
Dependent Claim
12 words
The method according to claim 11, wherein the circulatory disease is thrombosis.
Claim 14
Dependent Claim
12 words
The method according to claim 11, wherein the circulatory disease is shock.
Claim 15
Dependent Claim
12 words
The method according to claim 13, wherein the shock is endotoxin shock.
Claim 16
Dependent Claim
30 words
The method according to claim 1, wherein the compound (I) or a physiologically acceptable salt thereof is administered for the prevention or treatment of a platelet activating factor-induced allergic disease.
Claim 17
Dependent Claim
13 words
The method according to claim 15, wherein the allergic disease is respiratory stenosis.
Claim 18
Dependent Claim
19 words
The method according to any of claim 1 and claims 11-16, wherein the compound (I) is 3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-04-14 | 1989-10-14 | 1990-04-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-04-14 | 1993-10-14 | 1994-04-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-04-14 | 1997-10-14 | 1998-04-15 | $7700.00 | Window Closed / Lapsed |